Research study to evaluate the efficacy and safety of adjunctive Pimavanserin in subjects with major depressive disorder and inadequate response to antidepressant treatment.

Site Image

Study Overview

We are looking for individuals experiencing treatment-resistant symptoms of depression. This clinical research study is designed to help us understand the efficacy of Pimavanserin as an adjunctive therapy (in addition to another antidepressant) to your current SSRI/SNRI antidepressant. Participants will be randomly assigned either to receive the medication under investigation or a placebo to add to their current antidepressant medication for six weeks. Study participation will last for about 9 weeks (3 weeks screening; 6 weeks treatment) followed by a 30 days follow up period. 

 You may be eligible to participate if currently you are:
 • above 18 years of age 
• Have been treated with one of the SSRI/SNRI antidepressant as per protocol for at least 8 weeks with no relief
 • Have a bMI between 18.5 – 35 kg/m2 

 The clinician will discuss additional study requirements with you if necessary. All medications and treatment will be provided at no cost to you. Compensation for your time and travel may also be provided. On completion of the 6 weeks treatment period, individuals may be eligible to participate in a 52-week open-label extension study.

  • Study Identifier: 832801

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

If you need assistance finding a non-cancer study or if you have any questions, please email